Q4 2022 13F Holders as of 31 Dec 2022
-
Type / Class
-
Equity / Common Stock, par value $0.0001 per share
-
Shares outstanding
-
44,162,869
-
Total 13F shares
-
31,178,634
-
Share change
-
-667,401
-
Total reported value
-
$188,300,136
-
Price per share
-
$6.04
-
Number of holders
-
59
-
Value change
-
-$4,385,760
-
Number of buys
-
25
-
Number of sells
-
27
Institutional Holders of Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) as of Q4 2022
As of 31 Dec 2022,
Prelude Therapeutics Inc - Common Stock, par value $0.0001 per share (PRLD) was held by
59 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,178,634 shares.
The largest 10 holders included
BAKER BROS. ADVISORS LP, ORBIMED ADVISORS LLC, FMR LLC, UBS ASSET MANAGEMENT AMERICAS INC, VANGUARD GROUP INC, MASSACHUSETTS FINANCIAL SERVICES CO /MA/, BlackRock Inc., PRICE T ROWE ASSOCIATES INC /MD/, Candriam S.C.A., and BANK OF AMERICA CORP /DE/.
This page lists
59
institutional shareholders reporting positions in this security
for the Q4 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.